PresentationSo with that out of the way, let me turn it over to Immunocore's CEO, Bahija Jallal.Great. Good morning, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 44th Annual Healthcare Conference today with Immunocore. First, you're going to hear a presentation from the company, and then we're going to go into a Q&A session. [Operator Instructions].Bahija JallalCEO & Executive Director Good morning, and thank you, Jess, for having us. It's always a pleasure. Thi ...

PresentationJessica FyeJPMorgan Chase & Co, Research Division Great. Welcome. Good morning, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing our 44th Annual Healthcare Conference this morning with Legend. First, you're going to hear a presentation from the company and then we're going to go into a Q&A session. So for all of you in the room, if you want to ask a question, just raise your hands, someone will bring over a microphone. And if you're listening online, you can ...

Kyverna Therapeutics (NasdaqGS:KYTX) FY Conference January 14, 2026 12:45 PM ET Company ParticipantsWarner Biddle - CEONone - Video NarratorNone - TranslatorConference Call ParticipantsNone - Analyst 3None - Analyst 1None - Analyst 4Brian Cheng - Senior Biotech AnalystNone - Analyst 2Brian ChengGood morning. Thank you so much for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have Kyverna Therapeut ...

PresentationWelcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Rati Pinge, Priyanka Grover and Joyce Zhou. Our next presenting company is ProKidney. And presenting on behalf of the company, we have CEO, Bruce Culleton.Bruce CulletonCEO & Director Good morning, everyone. And thank you, Anupam and JPMorgan for inviting us back to the conference again. It's a pleasure to present this mor ...

PresentationGood morning, everyone. I'm Yang Huang, China Healthcare analyst of JPMorgan based in Hong Kong. Welcome to the third day of our JPMorgan Healthcare Conference. This morning's session is going to be kicked off by WuXi AppTec, and we have WuXi AppTec Co-CEO, Dr. Minzhang Chen, who is going to give us a presentation. Dr. Chen?Minzhang ChenCo-CEO & Executive Director All right. Thank you, Yang. Good morning, everyone. Happy New Year. I'm glad to be here first today to kick off the day. I hope our p ...

PresentationGood morning, everyone. I'm Yang Huang, China Healthcare analyst of JPMorgan based in Hong Kong. Welcome to the third day of our JPMorgan Healthcare Conference. This morning's session is going to be kicked off by WuXi AppTec, and we have WuXi AppTec Co-CEO, Dr. Minzhang Chen, who is going to give us a presentation. Dr. Chen?Minzhang ChenCo-CEO & Executive Director All right. Thank you, Yang. Good morning, everyone. Happy New Year. I'm glad to be here first today to kick off the day. I hope our p ...

Immunocore (NasdaqGS:IMCR) FY Conference January 14, 2026 11:15 AM ET Company ParticipantsBahija Jallal - CEODavid Berman - EVP of Research and DevelopmentTravis Coy - EVP and CFOConference Call ParticipantsJessica Fye - AnalystNone - AnalystJessica FyeGreat. Good morning, everyone. My name's Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 44th annual healthcare conference today with Immunocore. First, you're going to hear a presentation from the company, and then we're going to go int ...

Access the segment here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Timothy Lu, MD, PhD, CEO of Senti, discussed its recent news release announcing that the U.S. Food and Drug Administration (FDA) gra ...

PHILADELPHIA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”) on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the “Class Period”), inclusive. Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than January 16, 2026, s ...

Sarasota, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”) today announced that it will be presenting at the upcoming Sequire Investor Summit 2026. The fourth edition of the Sequire Investor Summit is scheduled for January 20th-22nd, 2026, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. “We appreciate the opportunity to present at the Sequire Investor Summit and discuss our novel approach to addressing the significant unmet medical need in concussion a ...